ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD) (PBAMD2)
Phase I/II Prospective, Randomized, Double-blinded Study of Intravitreal Anti-VEGF Therapy Combined With Proton Beam Radiation Versus Sham Irradiation in Treating Exudative Age-related Macular Degeneration
Sponsor: University of California, Davis
Listed as NCT01213082, this PHASE1/PHASE2 trial focuses on Exudative Age-related Macular Degeneration and remains completed. Sponsored by University of California, Davis, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, Davis
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .